



Raban Jeger

Contact

Raban Jeger

Publications (11)

Wagener M, Boeddinghaus J, Gaemperli O, Räber L, Nietlispach F, Meier P, Muller O, Weilenmann D, Jeger R. Trends in Coronary and Structural Heart Interventions in Switzerland over the Last 16 Years and Impact of COVID-19: Insights from the National Swiss PCI Survey. *J Clin Med* 2022; 11

Foster-Witassek F, Rickli H, Roffi M, Pedrazzini G, Eberli F, Fassa A, Jeger R, Fournier S, Erne P, Radovanovic D. Reducing gap in pre-hospital delay between women and men presenting with ST-Elevation myocardial infarction. *Eur J Prev Cardiol* 2022

Wagener M, Jeger R, Weilenmann D, Räber L, Nietlispach F, Muller O, Meier P, Gämperli O, Cook S, Twerenbold R, On Behalf Of The Swiss Working Group Interventional Cardiology Of The Swiss Society Of Cardiology. Coronary and structural heart interventions in Switzerland 2019. *Swiss Med Wkly* 2021; 151:w20495.

Sendi P, Knirsch W, Agyeman P, Zbinden S, Jeger R, Guery B, Boggian K, Fluckiger U, Frank M, Hasse B, Greutmann M. Infective endocarditis: prevention and antibiotic prophylaxis. *Swiss Med Wkly* 2021; 151:w20473.

Tersalvi G, Erne P, Moccetti T, Jeger R, Moccetti M, Eberli F, Roffi M, Rickli H, Radovanovic D, Biasco L, Pedrazzini G. Heavy Drinking Habits Are Associated with Worse In-Hospital Outcomes in Patients with Acute Coronary Syndrome: An Insight from the AMIS Plus Registry. *Cardiology* 2020; 145:757-765.

Hunziker L, Pilgrim T, Rickli H, Erne P, Urban P, Cuculi F, Pedrazzini G, Jeger R, Radovanovic D, AMIS Plus Registry Investigators are listed in alphabetic order with the names of the local principal investigators. Twenty-Year Trends in the Incidence and Outcome of Cardiogenic Shock in AMIS Plus Registry. *Circ Cardiovasc Interv* 2019; 12:e007293.

Gilgen N, Butter C, Bruch L, Kaiser C, Hoffmann A, Rickenbacher P, Mueller C, Stephan F, Coslovsky M, Jeger R, Krackhardt F, Zweiker R, Farah A, Scheller B, Ohlow M, Mangner N, Weilenmann D, Wöhrle J, Jamshidi P, Leibundgut G, Möbius-Winkler S, BASKET-SMALL 2 Investigators. Drug-coated balloons for de novo lesions in small coronary arteries: rationale and design of BASKET-SMALL 2. *Clin Cardiol* 2018; 41:569-575.

Biasco L, Erne P, Moccetti T, Jeger R, Eberli F, Roffi M, Rickli H, Moccetti M, Radovanovic D, Pedrazzini G. New-onset or Pre-existing Atrial Fibrillation in Acute Coronary Syndromes: Two Distinct Phenomena With a Similar Prognosis. *Rev Esp Cardiol (Engl Ed)* 2018

Kaiser C, Vuillomenet A, Steiner M, von Felten S, Vogt D, Wadt Hansen K, Rickenbacher P, Conen D, Müller C, Buser P, Hoffmann A, Pfisterer M, Weilenmann D, Rickli H, Galatius S, Jeger R, Gilgen N, Skov Jensen J, Naber C, Alber H, Wanitschek M, Eberli F, Kurz D, Pedrazzini G, Moccetti T, BASKET-PROVE II study group. Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome trial. *Circulation* 2014; 131:74-81.

Jeger R, Gilgen N, Vuillomenet A, Jensen J, Rickli H, Pedrazzini G, Naber C, Galatius S, Eberli F, Alber H, Pfisterer M, Kaiser C. Newest-generation drug-eluting and bare-metal stents combined with prasugrel-based antiplatelet therapy in large coronary arteries: the BASel Stent Kosten Effektivitäts Trial PROspective Validation Examination part II (BASKET-PROVE II) trial design. *Am Heart J* 2012; 163:136-41.e1.

Filipovic M, Jeger R, Probst C, Girard T, Pfisterer M, Gürke L, Skarvan K, Seeberger M. Heart rate variability and cardiac troponin I are incremental and independent predictors of one-year all-cause mortality after major noncardiac surgery in patients at risk of coronary artery disease. *Journal of the American College of Cardiology* 2003; 42:1767-76.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch